Get the Stockscreener App
19.42
0.54%
-0.105
After Hours:
20.05
0.63
+3.24%
Tandem Diabetes Care Inc stock is traded at $19.42, with a volume of 1.62M.
It is down -0.54% in the last 24 hours and up +3.24% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$19.52
Open:
$19.63
24h Volume:
1.62M
Relative Volume:
0.80
Market Cap:
$1.33B
Revenue:
$1.01B
Net Income/Loss:
$-204.71M
P/E Ratio:
-6.3276
EPS:
-3.0691
Net Cash Flow:
$-29.67M
1W Performance:
-4.62%
1M Performance:
+3.24%
6M Performance:
+38.71%
1Y Performance:
-2.80%
1-Day Range:
$19.18
$20.02
1-Week Range:
$17.59
$20.49
52-Week Range:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
19.42 | 1.34B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
89.46 | 158.14B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.73 | 120.69B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.00 | 103.96B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.50 | 85.62B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.98 | 48.14B | 6.30B | 1.07B | 1.34B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Upgrade | Truist | Hold → Buy |
| Mar-17-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-23-26 | Upgrade | Lake Street | Hold → Buy |
| Feb-20-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Buy |
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
FDA flags high-risk recall for Tandem Diabetes Mobi pumps - MSN
TD Cowen Raises Tandem Diabetes (TNDM) Price Target, Keeps Buy Rating - Insider Monkey
Vanguard Capital Management files 13G for Tandem Diabetes Care (NYSE: TNDM) — 3.55M shares - Stock Titan
10 Best Medical Stocks to Buy Under $30 - Insider Monkey
MSN Money - MSN
Tandem Diabetes Care Announces Upcoming Conference Presentations - Yahoo Finance
Vanguard Portfolio Management (TNDM) reports 4.05M shares, 5.91% stake - Stock Titan
Tandem Diabetes Care Opens with 5.69% Gain, Outpacing S&P 500's 2.51% Increase - Markets Mojo
TNDM Stock Chart | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
Strength seen in Tandem Diabetes Care (TNDM): Can its 9.1% jump turn into more strength? - MSN
Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes - BioSpace
Tandem Diabetes Care (TNDM) Corporate presentation Summary - Quartr
FDA clears Control-IQ+AID technology for use in pregnancy complicated by type 1 diabetes - Contemporary OB/GYN
Tandem rises as Piper Sandler upgrades on pharmacy strategy - MSN
TNDM: Tandem Diabetes Receives FDA Approval for Control-IQ+ in P - GuruFocus
Tandem Diabetes’ Control-IQ+ Wins FDA Nod for T1D in Pregnancy - Medical Product Outsourcing
Tandem gains as Truist becomes latest to upgrade on new pharmacy model - MSN
Tandem Diabetes Care, Inc. (TNDM) reports Q4 loss, tops revenue estimates - MSN
Tandem Diabetes upgraded at Citi on risk-reward setup - MSN
Stocks generating improved relative strength: Tandem Diabetes Care - MSN
Tandem Diabetes Care (TNDM) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Rothschild & Co Redburn Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
FDA flags most serious recall for Tandem Mobi insulin pumps - MSN
FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps - Benzinga
(TNDM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
B of A Securities upgrades Tandem Diabetes Care (TNDM) - MSN
Tandem Diabetes Care (TNDM) reports Q4 earnings: What key metrics have to say - MSN
Tandem Diabetes Care Inc (TNDM) Stock Up 3.7% and Still Underval - GuruFocus
Tandem recalls Mobi insulin pumps over software malfunction - MedTech Dive
A Look at Tandem Diabetes Care Inc (TNDM) After 3.0% Gain -- GF Value $33.02 vs Price $21.24 - GuruFocus
TNDM Maintained by TD Cowen -- Price Target Raised to $28.00 - GuruFocus
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Tandem Diabetes stock price target raised to $28 by TD Cowen - Investing.com Canada
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $28 - Moomoo
Tandem (TNDM) Stock: Downside Risk Overview (Slight Rise) 2026-04-18ATR Levels - Cổng thông tin điện tử Tỉnh Sơn La
Tandem Diabetes (TNDM) COO exercises RSUs; shares withheld for taxes - Stock Titan
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.8% -- What GF Score of 74 Tells Investors - GuruFocus
Mizuho Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $22 - Moomoo
Ideas Watch: Can Tandem Diabetes Care Inc continue delivering strong returnsPortfolio Performance Summary & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Does Tandem Diabetes Care Inc have pricing power2026 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
(TNDM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tandem Diabetes Care Inc Stock (TNDM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Mar 16 '26 |
Option Exercise |
0.00 |
7,414 |
0 |
43,383 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Mar 17 '26 |
Sale |
23.05 |
187 |
4,310 |
37,656 |
0.57%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):